Skip to main content

RX Updates

PsA Thumbnail

Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation

Sponsored by Novartis
Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation: results from the double-blind, randomised, phase 3 MAXIMISE trial.
Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Sponsored by Novartis Medical Affairs
The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.
Role of Risankizumab-rzaa

The Role of a Selective IL-23 p19 inhibitor for Patients with Psoriatic Arthritis

Sponsored by AbbVie Medical Affairs
Psoriatic arthritis is heterogeneous in symptoms and severity. A selective IL-23 p19 inhibitor with a 12-week maintenance dosing interval is approved for adults with active PsA
Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Sponsored by Novartis Medical Affairs
The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.
The Science of Upadacitinicib in Psoriatic Arthritis

The Science of Upadacitinib in Psoriatic Arthritis

Sponsored by AbbVie Medical Affairs
Cardiovascular events

Comorbidities in axSpA: A Focus on Cardiovascular Features

Sponsored by Novartis Medical Affairs
Patients with axial spondyloarthritis (axSpA) commonly experience cardiovascular (CV) comorbidities. There is a need to holistically assess a patient, including considerations for managing disease activity and understanding the safety profile of available therapies as it relates to comorbidities. Join Marina Magrey, MD as she provides insight on this topic for holistic patient-centered care.
Juvenile-Psoriatic Arthritis Rx Update

Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-Related Arthritis (ERA): Current Challenges and Future Outlook

Sponsored by Novartis Medical Affairs
There is a significant burden of disease associated with JPsA and ERA, with patients experiencing structural damage progression, risk of disability, and comorbidities that may persist into adulthood. This presentation led by Hermine Brunner, MD educates on the importance of early recognition and management.
Women in Rheumatology

Women Leaders in Rheumatology: Leadership in a Virtual World

Sponsored by Bristol Myers Squibb and the Bristol Myers Squibb Network of Women (B-NOW)
A moderated panel of prominent female rheumatologists will discuss the challenges and successes in clinical practice and research that they encountered during the COVID-19 pandemic.
EULAR 2021 Abstracts

Expert-Selected EULAR 2021 Abstracts

Sponsored by Novartis Medical Affairs
Didn’t have time to join EULAR 2021? Listen to a panel of experts as they present their views on the key abstracts in SpA and Still’s disease.
 Expert Perspectives on Lupus Nephritis

Expert Perspectives on Lupus Nephritis

Sponsored by GSK US Medical Affairs
In this disease education video series from GSK, leading rheumatologists and nephrologists share their perspectives on lupus nephritis and reflect upon the gaps that remain in our understanding and management of the disease.
April Novartis Spondyloarthritis Rx Update

Axial Involvement in Spondyloarthritis: A Patient-Centered Exploration

Sponsored by Novartis Medical Affairs
Listen to Ethan Craig, MD, MPH discuss 3 of his patient cases to identify and differentiate axial involvement within the spectrum of spondyloarthritis.
The Reflecting Rheum Rx Update

The Reflecting Rheum: 2020 SpA and Still’s Disease Highlights

Sponsored by Novartis Medical Affairs
Listen to a discussion of medical experts share their views on the most impactful work done in Spondyloarthritis and Still’s Disease in 2020.
×